Vandria's VNA-318 Shows Promising Phase 1 Results with Novel Dual-Action Mechanism for Alzheimer's Disease
核心洞察
Vandria's VNA-318, a first-in-class oral brain-penetrant small molecule, demonstrated excellent safety and tolerability in a Phase 1 trial involving 92 healthy male subjects with no severe adverse events.
Single doses of VNA-318 produced statistically significant (p<0.001) and dose-dependent changes in key plasma target engagement biomarkers, supporting its novel dual mechanism targeting inflammation (搜索) reduction and mitochondrial function (搜索) improvement.
The compound showed predictable pharmacokinetics with a long half-life supporting once-daily dosing and confirmed brain penetration in humans, validating preclinical findings.
Vandria SA has reported encouraging topline results from its first-in-human clinical trial of VNA-318, a novel oral brain-penetrant small molecule designed to treat Alzheimer's disease (搜索) through a dual mechanism targeting inflammation (搜索) reduction and mitochondrial function (搜索) improvement. The findings were presented at the 18th Clinical Trials in Alzheimer's Disease meeting in San Diego.
Novel Mechanism Targets Unmet Medical Needs
VNA-318 represents a first-in-class therapeutic approach, modulating a novel protein target with genetic associations to Alzheimer's disease (搜索) and related neurodegenerative conditions. The compound's dual mode of action addresses major unmet medical needs in Alzheimer's patients, specifically cognitive impairment (搜索) and the associated debilitating loss of function.
In preclinical mouse models of neurodegeneration (搜索) and cognitive impairment (搜索), VNA-318 demonstrated both immediate pro-cognitive benefits and long-term disease-modifying effects. The compound showed immediate improvements in memory, learning, and cognitive function, alongside long-term reductions in neuroinflammation (搜索), decreased toxic protein aggregation, and enhanced mitochondrial function (搜索).
Phase 1 Trial Demonstrates Strong Safety Profile
The Phase 1 trial (VNA-318-01) was a randomized, double-blind single and multiple ascending dose study involving 92 healthy male subjects. The interim results revealed an excellent safety and tolerability profile, with VNA-318 well tolerated across all dose levels without any safety concerns, severe or serious adverse events, or adverse events leading to trial discontinuation.
"We are very excited about the results of our first-in-human trial of VNA-318, which ticks all the boxes for a Phase 1 trial – and more," said Klaus Dugi M.D., CEO of Vandria. "The statistically significant dose-dependent change in a key target engagement biomarker is a very important finding and will be valuable for our Phase 2 clinical development strategy."
Promising Pharmacokinetic and Biomarker Data
The pharmacokinetic data demonstrated several favorable characteristics supporting clinical development. VNA-318 showed a long half-life supportive of once-daily oral dosing and exhibited a predictable, dose-linear increase of exposure with low variability.
Notably, single doses of VNA-318 resulted in statistically significant (p<0.001) and dose-dependent changes in a key plasma target engagement biomarker. This easily accessible biomarker will be leveraged in future clinical development phases.
Brain penetration measurements in cerebrospinal fluid from one trial cohort confirmed that the brain penetration observed in preclinical studies successfully translates to humans, with VNA-318 levels reaching concentrations predictive of therapeutic efficacy based on preclinical studies in both acute pro-cognitive and long-term disease-modifying models of Alzheimer's disease (搜索) pathophysiology.
Broader Therapeutic Potential
Given its broad mechanism of action, VNA-318 has potential applications beyond Alzheimer's disease (搜索). Dugi noted that the company believes VNA-318 could address unmet medical needs in mild cognitive impairment (搜索) associated with Alzheimer's disease and Major Depressive Disorder (搜索), as well as other CNS disorders.
Steven Arnold M.D., Professor of Neurology at Harvard Medical School and EGC Endowed Chair in Alzheimer Therapeutic Sciences at Massachusetts General Hospital, commented: "VNA-318 modulates a novel target with genetic associations with Alzheimer's disease (搜索) and related neurodegenerative diseases. It is very exciting to see the compelling data from Vandria's preclinical and clinical studies, and the progress VNA-318 is making as it gets closer to being tested in patients."
Development Timeline and Market Opportunity
Vandria is planning to raise a Series B funding round in 2026 to support proof-of-concept Phase 2 trials. The global Alzheimer's market is estimated at $6 billion and is expected to grow at a compound annual growth rate of 12% through 2035, driven by an aging population, improved diagnosis, and growing awareness of the condition.
The planned Series B funding will also support progression of Vandria's preclinical pipeline of compounds targeting non-CNS indications including muscle, lung, and liver diseases. The Swiss-based company has previously raised $32 million in venture financing from investors including +ND Capital, Hevolution Foundation, and Dolby Family Ventures.